| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/18/2002 | US20020045203 Method for detecting active ingredients of medical value |
| 04/18/2002 | US20020044936 Administering a monoclonal antibody or fragment thereof which acts as an antagonist of the integrins GPIIb/IIIa ( alpha IIb beta 3) and alpha v beta 3; also treating inflammatory diseases such as rheumatoid arthritis, psoriasis |
| 04/18/2002 | DE10050995A1 New benzylic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease |
| 04/18/2002 | DE10050994A1 New diphenylalkanoic acid azabicyclooctane ester quaternary salts useful as anticholinergic agents, especially in treatment of asthma and chronic obstructive pulmonary disease |
| 04/18/2002 | DE10050663A1 Use of amino-substituted imidazo(1,2-a)pyridine, imidazo(1,2-a)pyrimidine and imidazo(1,2-a)pyrazine derivatives as NO synthase inhibitors, e.g. in treatment of migraine and neurodegenerative diseases |
| 04/18/2002 | CA2459746A1 Pyrimidinone derivatives and their use in the treatment of atherosclerosis |
| 04/18/2002 | CA2427499A1 Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppar-.gamma. binding agents |
| 04/18/2002 | CA2425771A1 Selective maxi-k- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| 04/18/2002 | CA2425678A1 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425674A1 Sulfide and disulfide compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425672A1 Use of substituted imidazo[1,2-a]-pyridin-,pyrimidin-and -pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting nos |
| 04/18/2002 | CA2425610A1 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 04/18/2002 | CA2425581A1 Modulation of ligand binding/enzymatic activity of alpha beta proteins |
| 04/18/2002 | CA2425416A1 Novel aminophenyl piperazine or aminophenyl piperidine derivatives inhibiting prenyl transferase proteins and methods for preparing same |
| 04/18/2002 | CA2425121A1 Ether compounds and compositions for cholesterol management and related uses |
| 04/18/2002 | CA2425001A1 Novel serine protease genes related to dppiv |
| 04/18/2002 | CA2424983A1 Nucleic acid molecules and polypeptides for immune modulation |
| 04/18/2002 | CA2424951A1 Beta-amino acid derivatives as integrin receptor antagonists |
| 04/18/2002 | CA2424802A1 Novel aminotriazolone compounds, method for preparing same and pharmaceutical compositions containing same |
| 04/18/2002 | CA2424292A1 Tricyclic compounds and uses thereof |
| 04/18/2002 | CA2424107A1 Sulfonylguanidines |
| 04/18/2002 | CA2394084A1 Inhibitors of protein kinases |
| 04/17/2002 | EP1197550A2 Methods and compositions for diagnosing and treating disorders involving angiogenesis |
| 04/17/2002 | EP1197493A1 Benzimidazole compounds |
| 04/17/2002 | EP1197488A1 (2S)-2-(Adamantan-1-ylmethoxycarbonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionic acid isopropyl ester, its preparation and its use |
| 04/17/2002 | EP1197487A1 Benzimidazole compounds and drugs containing the same |
| 04/17/2002 | EP1197485A1 Cyclobuten-dione derivatives for use in the treatment of artherosclerosis |
| 04/17/2002 | EP1197484A2 1H-Indole-3-glyoxylamide sPLA2 inhibitors |
| 04/17/2002 | EP1197226A1 Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| 04/17/2002 | EP1197223A1 Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy |
| 04/17/2002 | EP1197210A1 Agents inhibiting chronic rejection reactions after organ transplantation |
| 04/17/2002 | EP1196783A2 Screening for therapeutic agents being scap antagonists |
| 04/17/2002 | EP1196638A1 USE OF THE i KRIT1 /i GENE IN ANGIOGENESIS |
| 04/17/2002 | EP1196635A2 Cell death related drug targets in yeast and fungi |
| 04/17/2002 | EP1196577A2 Cell cycle and proliferation proteins |
| 04/17/2002 | EP1196574A2 Human proteins involved in detoxification |
| 04/17/2002 | EP1196569A2 Electron transfer proteins |
| 04/17/2002 | EP1196568A1 Human lim domain proteins |
| 04/17/2002 | EP1196567A2 Human immune response molecules |
| 04/17/2002 | EP1196564A2 Atherosclerosis-associated genes |
| 04/17/2002 | EP1196444A1 Peptides that lower blood glucose levels |
| 04/17/2002 | EP1196441A1 Keratinocyte growth factor-2 |
| 04/17/2002 | EP1196440A2 Therapeutic peptides derived from subsequences of bpi |
| 04/17/2002 | EP1196433A2 CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN ALPHA v BETA 6 |
| 04/17/2002 | EP1196419A1 Potassium channel blocking agents |
| 04/17/2002 | EP1196411A1 Bradykinin b1 receptor antagonists |
| 04/17/2002 | EP1196407A1 N-imidazolylmethyl carboxamides as nitric oxide production inhibitors |
| 04/17/2002 | EP1196404A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 04/17/2002 | EP1196400A1 Amino-alkyl derivatives |
| 04/17/2002 | EP1196394A1 Novel carboxylic acid derivatives with 5,6 substituted pyrimidine ring, the production and utilization thereof as endothelin receptor antagonists |
| 04/17/2002 | EP1196391A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 04/17/2002 | EP1196390A2 Pyrazole compositions useful as inhibitors of erk |
| 04/17/2002 | EP1196387A1 Azo amino acid derivatives for the treatment of neurological diseases |
| 04/17/2002 | EP1196386A2 N-substituted glycine derivatives |
| 04/17/2002 | EP1196385A1 Beta-amino acid derivatives for the treatment of neurological diseases |
| 04/17/2002 | EP1196383A1 Process for preparing amlodipine benzenesulphonate |
| 04/17/2002 | EP1196379A2 INHIBITORS OF FACTOR Xa |
| 04/17/2002 | EP1196373A1 3-amino-2-benzyl-1-phenyl-propane derivatives |
| 04/17/2002 | EP1196194A2 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 04/17/2002 | EP1196186A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 04/17/2002 | EP1196180A1 Treatment of angiogenesis dependent conditions with dextrin sulphate |
| 04/17/2002 | EP1196176A1 Use of beta-napthoquinone for making medicines having an inhibiting effect on the release of glutamate by the brain |
| 04/17/2002 | EP1196169A1 Compounds having cytokine inhibitory activity |
| 04/17/2002 | EP1196167A1 Method of reducing neuronal injury or apoptosis |
| 04/17/2002 | EP1196166A1 Azetidine carboxamide derivatives for the treatment of cns disorders |
| 04/17/2002 | EP1196165A2 Azetidine compounds in cns and eye diseases |
| 04/17/2002 | EP1196152A1 Use of cortisol antagonists in the treatment for heart failure |
| 04/17/2002 | EP1196151A1 Transdermal therapeutic system for administering a calcium antagonist |
| 04/17/2002 | EP1196129A1 Method for scavenging radicals with urocanic acid, derivatives and analogues |
| 04/17/2002 | EP1196047A1 Prophylactic dietary supplement based on milk |
| 04/17/2002 | EP1196043A1 An effervescent green tea extract formulation |
| 04/17/2002 | EP1152755B1 Essential fatty acids in the prevention of cardiovascular events |
| 04/17/2002 | EP1051086B1 Dietetic composition in the form of a substitution salt for table salt |
| 04/17/2002 | EP1028730B1 Compositions of lipid lowering agents |
| 04/17/2002 | EP0998475B1 Novel compounds |
| 04/17/2002 | EP0996620B1 Novel compounds |
| 04/17/2002 | EP0937038B1 Vitamin d analogues |
| 04/17/2002 | EP0888313B1 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors |
| 04/17/2002 | EP0831911B1 Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
| 04/17/2002 | EP0831902A4 Muscle trophic factor |
| 04/17/2002 | EP0807632B1 Pyrroloazepine derivatives |
| 04/17/2002 | EP0607178B1 Methods for the isolation and fusion of cells |
| 04/17/2002 | CN1345335A Melanocortin receptor ligands |
| 04/17/2002 | CN1345332A C-terminal modified (N-substituted)-2 indolylcarbonyldiptides as inhibitors of ICE/CED-3 family of cysteine proteases |
| 04/17/2002 | CN1345331A Method and composition for angiogenesis inhibition |
| 04/17/2002 | CN1345329A Tumor mecrosis factor receptors 6 alpha and beta |
| 04/17/2002 | CN1345320A Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
| 04/17/2002 | CN1345319A Triazole compounds with dopamine-D3-receptor affinity |
| 04/17/2002 | CN1345318A Triazole compounds with dopamine -D3-receptor affinity |
| 04/17/2002 | CN1345317A (1-phenacy-3-phenyl-3-piperidylethyl)piperidine derivatives, method for production thereof and pharmaceutical compositions containing the same |
| 04/17/2002 | CN1345314A Amine derivatives as protease inhibitors |
| 04/17/2002 | CN1345312A Dibenzoazulene derivatives for treating thrombosis, osteoporosis arteriosclerosis |
| 04/17/2002 | CN1345311A 1-arenesulfonyl-2-aryl-pyrolidine and piperidine derivatives for treatment of CNS disorders |
| 04/17/2002 | CN1345309A Diaryl derivatives and their use as medicaments |
| 04/17/2002 | CN1345308A Acetylenic alpha-amino acid based sulfonamide hydroxamic acid TACE inhibitors |
| 04/17/2002 | CN1345307A N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 04/17/2002 | CN1345303A Oxamic acids and derivatives as thyroid receptor ligands |
| 04/17/2002 | CN1345245A Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 04/17/2002 | CN1345244A Herbal compositions and uses for treatment tof allergic reactions |
| 04/17/2002 | CN1345239A Heterocyclic containing biphenyl alpha P2 inhibitors and method |